SecSonar.com

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Inhibrx Biosciences, Inc. (INBX) is a Biotechnology company based in US with a market capitalization of $1.5B. Revenue grew 550.0% year-over-year and free cash flow was negative at -$129.8M. This page tracks INBX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 156 employees · IPO Jun 4, 2024

Valuation

Valuation & price

$108.64 · as of May 17, 2026 · -23.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

190.48

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$142$80.09$18.35Jul 25Dec 25Jul 26Jul 7, 25$18.35Jul 9, 25$20.92Jul 11, 25$21.77Jul 15, 25$22.96Jul 17, 25$23.62Jul 21, 25$22.12Jul 23, 25$23.20Jul 25, 25$23.08Jul 29, 25$24.26Jul 31, 25$21.92Aug 4, 25$21.80Aug 6, 25$20.98Aug 11, 25$21.40Aug 13, 25$23.57Aug 15, 25$23.33Aug 19, 25$23.00Aug 21, 25$24.16Aug 25, 25$25.04Aug 27, 25$27.40Aug 29, 25$28.20Sep 3, 25$27.80Sep 5, 25$28.18Sep 9, 25$29.59Sep 11, 25$28.45Sep 16, 25$26.57Sep 18, 25$26.65Sep 22, 25$27.12Sep 24, 25$29.70Sep 26, 25$32.68Sep 30, 25$33.68Oct 2, 25$35.07Oct 6, 25$34.96Oct 8, 25$33.61Oct 10, 25$32.47Oct 14, 25$34.81Oct 16, 25$36.60Oct 21, 25$37.52Oct 23, 25$28.36Oct 27, 25$58.85Oct 29, 25$77.05Oct 31, 25$81.66Nov 4, 25$81.99Nov 6, 25$80.99Nov 10, 25$79.00Nov 12, 25$73.32Nov 14, 25$79.13Nov 18, 25$77.59Nov 20, 25$79.84Nov 25, 25$82.68Nov 28, 25$84.12Dec 2, 25$82.25Dec 4, 25$87.41Dec 8, 25$93.51Dec 10, 25$84.51Dec 12, 25$79.57Dec 16, 25$81.57Dec 18, 25$85.32Dec 22, 25$87.52Dec 24, 25$80.36Dec 29, 25$79.27Jan 2, 26$75.04Jan 6, 26$76.10Jan 8, 26$75.20Jan 12, 26$75.94Jan 14, 26$75.93Jan 16, 26$72.27Jan 21, 26$75.10Jan 23, 26$74.66Jan 27, 26$73.49Jan 29, 26$72.56Feb 2, 26$82.23Feb 4, 26$82.56Feb 9, 26$86.49Feb 11, 26$81.99Feb 13, 26$75.80Feb 18, 26$81.58Feb 20, 26$78.64Feb 24, 26$79.50Feb 26, 26$77.23Mar 2, 26$77.49Mar 4, 26$74.63Mar 6, 26$69.18Mar 10, 26$71.63Mar 12, 26$69.30Mar 17, 26$69.71Mar 19, 26$64.87Mar 23, 26$64.63Mar 25, 26$66.46Mar 27, 26$58.39Mar 31, 26$67.23Apr 2, 26$63.53Apr 7, 26$62.35Apr 9, 26$75.75Apr 13, 26$77.46Apr 15, 26$83.60Apr 17, 26$88.23Apr 22, 26$115.09Apr 24, 26$129.06Apr 28, 26$130.67Apr 30, 26$129.21May 4, 26$127.95May 6, 26$141.84May 8, 26$134.35May 12, 26$108.65May 14, 26$116.16May 18, 26$105.80May 20, 26$110.01May 22, 26$101.32May 28, 26$103.98Jun 1, 26$99.29Jun 3, 26$95.22Jun 5, 26$87.01Jun 9, 26$89.10Jun 11, 26$93.54Jun 15, 26$93.51Jun 17, 26$94.20Jun 22, 26$93.30Jun 24, 26$95.14Jun 26, 26$94.81Jul 2, 26$97.58
$18.3552-week range$141.84
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

550.0%

Revenue growth (YoY)

-91.0%

Gross margin

-$129.8M

Free cash flow (USD)

-$17.2M

Net debt

Net cash position

7.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$6.7MFY 2017$8.0MFY 2018$7.5MFY 2019$9.1MFY 2020$12.8MFY 2021$7.1MFY 2022$2.2MFY 2023$1.8MFY 2024$200.0KFY 2025$1.3M
$6.7M$1.3M

Free cash flow by year

2016 → 2025

FY 2016$-18.3MFY 2017$-20.1MFY 2018$-24.5MFY 2019$-33.9MFY 2020$-49.3MFY 2021$-81.2MFY 2022$-116.0MFY 2023$-197.9MFY 2024$-197.0MFY 2025$-129.8M
-$18.3M-$129.8M

Gross margin by year

2021 → 2025

FY 202162.3%FY 2022-4926.7%FY 202333.8%FY 2024-1042.5%FY 2025-91.0%
62.3%-91.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $-2.15)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventBLA Filing AcceptedJun 15, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 3, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • 8-K eventEarnings ReleaseMay 14, 2026Filing
  • 8-K eventClinical Trial UpdateMay 11, 2026Filing
  • 8-K eventClinical Trial UpdateApr 21, 2026Filing

Questions

Frequently asked questions

What is Inhibrx Biosciences, Inc.'s market cap?

Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.5B.

What is INBX's P/E ratio?

A meaningful P/E ratio is not available for INBX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is INBX's price-to-book (P/B) ratio?

INBX trades at 190.48 times book value per share.

When did Inhibrx Biosciences, Inc. last report earnings?

INBX last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying INBX stock?

SEC Form 4 filings show no open-market insider buys at Inhibrx Biosciences, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

IMTX

Immatics N.V.

$1.5B

ARDX

Ardelyx, Inc.

$1.5B

NRIX

Nurix Therapeutics, Inc.

$1.5B

MAZE

Maze Therapeutics, Inc.

$1.5B

TSHA

Taysha Gene Therapies, Inc.

$1.5B

IMCR

Immunocore Holdings plc

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.